Cholamandalam MS General Insurance Company standalone net profit rises 104.28% in the June 2024 quarter

Cholamandalam MS General Insurance Company standalone net profit rises 104.28% in the June 2024 quarter


Sales rise 12.51% to Rs 1318.83 crore

Net profit of Cholamandalam MS General Insurance Company rose 104.28% to Rs 133.76 crore in the quarter ended June 2024 as against Rs 65.48 crore during the previous quarter ended June 2023. Sales rose 12.51% to Rs 1318.83 crore in the quarter ended June 2024 as against Rs 1172.17 crore during the previous quarter ended June 2023.

ParticularsQuarter EndedJun. 2024Jun. 2023% Var.Sales1318.831172.17 13 OPM %13.437.47 PBDT178.9687.75 104 PBT178.9687.75 104 NP133.7665.48 104

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Aug 19 2024 | 5:55 PM IST



Source link

Cholamandalam MS General Insurance Company standalone net profit rises 104.28% in the June 2024 quarter

Capsave Finance Pvt standalone net profit rises 28.87% in the June 2024 quarter


Sales rise 25.09% to Rs 92.98 crore

Net profit of Capsave Finance Pvt rose 28.87% to Rs 21.87 crore in the quarter ended June 2024 as against Rs 16.97 crore during the previous quarter ended June 2023. Sales rose 25.09% to Rs 92.98 crore in the quarter ended June 2024 as against Rs 74.33 crore during the previous quarter ended June 2023.

ParticularsQuarter EndedJun. 2024Jun. 2023% Var.Sales92.9874.33 25 OPM %75.5075.30 PBDT32.5425.77 26 PBT29.9922.86 31 NP21.8716.97 29

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Aug 19 2024 | 5:55 PM IST



Source link

TruAlt Bioenergy files IPO papers with Sebi as it aims to mop up Rs 750 cr

TruAlt Bioenergy files IPO papers with Sebi as it aims to mop up Rs 750 cr



Leading biofuel producer TruAlt Bioenergy Ltd has filed preliminary papers with capital markets regulator Sebi to raise funds through an initial public offering (IPO).


The IPO is a mix of fresh issuance of equity shares worth Rs 750 crore and an offer for sale (OFS) of up to 36 lakh equity shares by promoters, according to the draft red herring prospectus (DRHP.


The OFS consists of up to 18 lakh equity shares each by Dhraksayani Sangamesh Nirani and Sangamesh Rudrappa Nirani.


The company may consider raising Rs 150 crore under the pre-IPO placement round. If such placement is completed, the fresh issue size will be reduced.


Out of the proceeds from the fresh issuance, Rs 425 crore will be utilised for funding working capital requirements, Rs 172.68 crore for setting up multi-feed stock operations, besides, a portion will be used for general corporate purposes.


Based in Bengaluru, TruAlt Bioenergy focuses on ethanol production, with a daily production capacity of 1,400 kilolitres(KLPD).


The company plans to boost its production capacity by an additional 600 KLPD across three locations and aims for 2,000 KLPD by October 2024.


TruAlt is diversifying into new areas like second-generation (2G) ethanol, utilising surplus bagasse — a byproduct of sugar production — as a raw material.


Also, the company plans to use 8,00,000 MT of bagasse from its promoter group companies to produce about 6 crore litres of 2G ethanol annually.


TruAlt’s business performance is heavily influenced by the price and availability of raw materials like sugar syrup and molasses.


To reduce reliance on these seasonal resources, the company plans to shift its focus towards producing grain-based ethanol.


This strategic move will help control material costs, optimise revenue, and maintain consistent ethanol production.


TruAlt Bioenergy’s revenue from operations was Rs 1,223.40 crore and profit after tax stood at Rs 31.81 crore in FY24.


DAM Capital Advisors and SBI Capital Markets are the book-running lead managers to the company’s IPO.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Aug 19 2024 | 5:08 PM IST



Source link

Cholamandalam MS General Insurance Company standalone net profit rises 104.28% in the June 2024 quarter

Benchmarks end flat; broader mkt rallies; metal stocks shine


The equity barometers ended near the flat line on Monday. The Nifty settled above the 24,550 mark. Metal, oil & gas and PSU bank shares were in demand. On the other hand, auto, private bank and bank stocks slipped.

As per provisional closing data, the barometer index, the S&P BSE Sensex, declined 12.16 points or 0.02% to 80,424.68. The Nifty 50 index added 31.50 points or 0.13% to 24,572.65.

The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index jumped 0.53% and the S&P BSE Small-Cap index rallied 1.33%.

The market breadth was strong. On the BSE, 2,710 shares rose and 1,318 shares fell. A total of 137 shares were unchanged.

Economy:

Indias forex reserves declined $4.8 billion to $670.119 billion for the week ended August 9, according to the latest RBI data.

In the previous reporting week, the countrys foreign exchange reserves had increased $7.533 billion to an all-time high of $674.919 billion.

For the week ended August 9, foreign currency assets, a major component of the reserves, decreased by $4.079 billion to $587.96 billion.

Gold reserves declined by $860 million to $59.239 billion during the week. The special drawing rights (SDRs) were up by $121 million to $18.282 billion.

Indias reserve position with the IMF increased by $18 million to $4.638 billion in the reporting week, the central bank data showed.

IPO Update:

The initial public offer (IPO) of Interarch Building Products received 1,19,92,112 bids for shares as against 46,91,585 shares on offer, according to stock exchange data at 15:45 IST on Monday (19 August 2024). The issue was subscribed 2.46 times.

The issue opened for bidding on Monday (19 August 2024) and it will close on Wednesday (21 August 2024). The price band of the IPO is fixed between Rs 850 to Rs 900 per share. An investor can bid for a minimum of 16 equity shares and in multiples thereof.

Stocks in Spotlight:

Piramal Enterprises (PEL) rallied 3.89% after the NBFC informed that its promoter group entity purchased 6.16 lakh equity shares, representing 0.27% of the total paid-up share capital of the company.

Meanwhile, the board of PEL will meet on Wednesday, 21 August 2024 to consider issuing non-convertible debentures (NCDs) aggregating up to Rs 150 crore on private placement basis.

Glenmark Pharmaceuticals gained 4.05% after the companys subsidiary Glenmark Therapeutics Inc., USA, announced the launch of OTC product Olopatadine Hydrochloride Ophthalmic Solution.

DCX Systems was locked in an upper circuit of 5% after the company informed that it has received orders worth Rs 107.08 crore from domestic and overseas customers.

Veranda Learning Solutions advanced 4.98% after the company said that it has partnered with Jumeira University Connect, the training arm of Jumeira University, to introduce a Chartered Accountancy (CA) preparation course for students in the UAE.

Genus Power Infrastructures was locked in an upper circuit of 5% after the company announced that its wholly-owned subsidiary received three letters of awards (LOA) worth totaling to Rs 2,925.52 crore.

Caplin Point Laboratories surged 16.20% after the Brazilian Health Regulatory Agency (ANVISA) concluded its inspection at Gummidipoondi facility, in Chennai in Tamil Nadu with zero observations.

JNK India rallied 3.24% after the heating equipment maker on Friday announced that it has received a ‘major order from Hindustan Petroleum Corporation (HPCL).

Techno Electric & Engineering Company (Techno Electric) jumped 4.50% after the company partnered with IndiGrid to develop two IndiGrids Greenfield interstate transmission Systems (ISTS) projects.

Global Markets:

Europeans stocks declined while Asian stocks traded mixed on Monday as investors weighed optimism about a US economic soft landing against concerns over the global growth outlook.

Expectations of cooling inflation and a potential easing cycle by the Federal Reserve buoyed sentiment. However, investors remained cautious ahead of key US economic data this week and Federal Reserve Chair Jerome Powell’s speech on Friday.

In Asia, market participants will closely monitor central bank meetings in Indonesia and South Korea for potential rate adjustments. Thailand’s policy decision is particularly awaited given uncertainties surrounding the new government’s economic plans.

US stocks rebounded from earlier losses to close higher on Friday, as a report showing improved consumer sentiment boosted investor confidence. The Dow Jones Industrial Average rose 0.24%, the S&P 500 climbed 0.20% and the Nasdaq Composite gained 0.21%.

The University of Michigans gauge of consumer sentiment rose to 67.8 in a preliminary August reading, up from 66.4 in the prior month. It is the first gain after four months of declines.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Aug 19 2024 | 3:52 PM IST



Source link

Strides Pharma falls over 4% after USFDA gives VAI tag to Chennai facility

Strides Pharma falls over 4% after USFDA gives VAI tag to Chennai facility


Strides Pharma Science shares fall: Shares of pharmaceutical company Strides Pharma Science fell 4.13 per cent to Rs 1,257 during intra-day trading on Monday. The drop came after Strides Alathur, a wholly-owned subsidiary of Strides Pharma Science, received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA). This EIR pertains to the conclusion of a Good Manufacturing Practices (GMP) inspection at the company’s formulations facility in Alathur, Chennai, conducted between April 1-5, 2024. According to a regulatory filing on the BSE, the USFDA classified the inspection status of this facility as ‘Voluntary Action Indicated’ (VAI). 


Strides Alathur facility caters to the US and Other Regulated Markets. The facility manufactures tablets & capsules and supports several current and future products for the US markets.


Headquartered in Bengaluru, Strides Pharma Science operates globally, focusing primarily on regulated markets. The company also follows an ‘in Africa for Africa’ strategy and has an institutional business that services donor-funded markets. Strides Pharma’s manufacturing sites are located across India (Chennai, Puducherry, and Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The company claims to focus on ‘difficult to manufacture’ products sold in over 100 countries


As of August 19, 2024, Strides Pharma Science boasts a market capitalisation of Rs 11,885.60 crore and is part of the BSE SmallCap index. Over the last year, the company’s shares have delivered consistent returns, with a year-to-date gain of 97.64 per cent. Over the past year, the stock has surged 212.17 per cent, according to BSE analytics.


Strides Pharma Science shares have a 52-week range of Rs 1,339.90 to Rs 412.45 on the BSE. 


As of 02:30 PM on Monday, the stock was trading at Rs 1287.05, down 2.02 per cent from its previous close of Rs 1,313.65 on the BSE. Around 0.34 lakh equity shares worth Rs 4.36 crore were exchanged during the session.

First Published: Aug 19 2024 | 3:00 PM IST



Source link

YouTube
Instagram
WhatsApp